Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $28.1 million.

  • Regenxbio's Receivables - Net rose 1709.43% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 1709.43%. This contributed to the annual value of $20.9 million for FY2024, which is 1782.59% down from last year.
  • Latest data reveals that Regenxbio reported Receivables - Net of $28.1 million as of Q3 2025, which was up 1709.43% from $21.8 million recorded in Q2 2025.
  • Over the past 5 years, Regenxbio's Receivables - Net peaked at $48.7 million during Q3 2021, and registered a low of $16.4 million during Q1 2024.
  • Moreover, its 5-year median value for Receivables - Net was $28.1 million (2025), whereas its average is $29.4 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first plummeted by 6121.34% in 2021, then soared by 1864.72% in 2025.
  • Quarter analysis of 5 years shows Regenxbio's Receivables - Net stood at $34.7 million in 2021, then decreased by 14.74% to $29.6 million in 2022, then decreased by 13.84% to $25.5 million in 2023, then fell by 17.83% to $20.9 million in 2024, then surged by 34.21% to $28.1 million in 2025.
  • Its Receivables - Net stands at $28.1 million for Q3 2025, versus $21.8 million for Q2 2025 and $19.4 million for Q1 2025.